Citations

Clear

127 citation(s) found for "Shari, G".

The Relationship Between Frailty and Decreased Physical Performance With Death on the Kidney Transplant Waiting List
Lorenz, Elizabeth C. , Cosio, Fernando G., Bernard, Shari, Bogard, Steven D., Bjerke, Brian R., Geissler, Elizabeth N., Hanna, Steven W., Kremers, Walter K. , Cheng, Yijing, Stegall, Mark D. , Bernard, Shari L, Stegall, Mark D , Kremers, Walter K , Cheville, Andrea , LeBrasseur, Nathan K.

Mayo Clinic

Progress in Transplantation | March 18, 2019 | Volume: 29 | Issue: 2 | Pages: 108-114

10.1177/1526924819835803 | PMID 30879429 Get It

Introduction: Frailty and decreased physical performance are associated with poor outcomes after kidney transplant. Less is known about their relationship with pretransplant outcomes. The aim of this study was to characterize associations between frailty and physical performance with death on the kidney transplant waiting list. Design: Since December 2014, high-risk kidney transplant candidates at our center (age > 59, diabetic and/or history of >3 years dialysis) have undergone frailty and physical performance testing using Fried Criteria and the Short Physical Performance Battery. Results: Between December 2014 and November 2016, 272 high-risk candidates underwent testing and were approved for transplant. Both frailty and physical performance score were significantly associated with death on the waiting list (hazard ratio [HR]: 6.7, confidence interval [CI]: 1.5-30.1; P = .01; HR: 0.8 per 1-point increase, CI: 0.7-1.0; P = .02, respectively). The relationship between frailty, physical performance score, and death on the waiting list appeared to be independent of age, diabetes, or duration of dialysis. Discussion: Frailty and decreased physical performance appear to be independently associated with increased mortality on the kidney transplant waiting list. Further studies are needed to determine whether improving frailty and physical performance prior to transplant can decrease waiting list mortality.
Expertise in Head and Neck Cutaneous Reconstructive Surgery
Deng, Min , Higgins, H. William , Lesiak, Kendra, Decker, Ashley B., Regula, Christie G., Stevenson, Mary L. , Raphael, Brian A., DePry, Jennifer L., Scott, Jeffrey F. , Bangash, H. , Ochoa, Shari A. , Ibrahimi, Omar A. , Shafai, Aria, Bordeaux, Jeremy S. , Carucci, John A. , Cook, Jonathan L. , Goldman, Glenn D., Rohrer, Thomas E. , Lawrence, Naomi, Deng, Min, Decker, Ashley

Mayo Clinic

Dermatologic Surgery | March 13, 2019 | Volume: 45 | Issue: 6 | Pages: 782-790

10.1097/dss.0000000000001844 | PMID 30829776 Get It

BACKGROUND The management of skin cancers has evolved with the development of Mohs micrographic surgery and a greater emphasis on surgical training within dermatology. It is unclear whether these changes have translated into innovations and contributions to the reconstructive literature. OBJECTIVE To assess contributions from each medical specialty to the cutaneous head and neck oncologic reconstructive literature. METHODS The authors conducted a systematic review of the head and neck reconstructive literature from 2000 through 2015 based on a priori search terms relating to suture technique, linear closure, advancement, rotation, transposition and interpolation flaps, and identified the specialty of the senior authors. RESULTS The authors identified 74,871 articles, of which 1,319 were relevant. Under suture technique articles, the senior authors were primarily dermatologists (58.2%) and plastic surgeons (20.3%). Under linear closure, the authors were dermatologists (48.1%), plastic surgeons (22.2%), and otolaryngologists (20.4%). Under advancement and rotation flaps, the senior authors were plastic surgeons (40.5%, 38.9%), dermatologists (38.1%, 34.2%), and otolaryngologists (14.4%, 21.6%). Under transposition and interpolation flaps, the senior authors were plastic surgeons (47.3%, 39.4%), dermatologists (32.3%, 27.0%), and otolaryngologists (15.3%, 23.4%). CONCLUSION The primary specialties contributing to the cutaneous head and neck reconstructive literature are plastic surgery, dermatology, and otolaryngology.
Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 515-515

10.1200/jco.2015.33.15_suppl.515 Get It

BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: Patterns, motivations, and implications for treatment decisions.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Larsen, Bryce G., Tamimi, Rulla M. , Borges, Virginia F. , Garber, Judy E. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6548-6548

10.1200/jco.2014.32.15_suppl.6548 Get It

The laser time out; Ensuring safe operation of lasers in the operating room suite
Ryan, Marthalane M., McCormick, Shari, Schaitberger, Sharli, Baldea, Barb, Hinni, Michael L.

Mayo Clinic

ILSC 2013: Proceedings of the International Laser Safety Conference | October 16, 2018 | Volume: No volume available | Issue: No issue available | Pages: 213-216

10.2351/1.5056793 Get It

Airway fires in the surgical suite are catastrophic and deadly. When there is a combination of an endotracheal (ET) tube filled with oxygen and an ignition source such as a laser, the standard ET tube acts like a blowtorch in the patient’s trachea. These tubes can be ignited at oxygen levels as low as 26% [1]. Laser safety programs should incorporate measures to isolate the triad that is present in all Operating Room (OR) fires: a source of oxygen, fuel, and ignition. Although safety hazards are inherent when lasers are used in the OR, they can be significantly reduced, if not eliminated, if proper procedures are implemented and adhered to whenever a laser is utilized in the OR. This article reviews the safety hazards and the implementation of a “Laser Time Out” to allow for the safe use of lasers in the Operating Room.
Pregnancy after breast cancer: Results from a prospective cohort study.
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 10065-10065

10.1200/jco.2017.35.15_suppl.10065 Get It

10065 Background: Prospective data regarding fertility and pregnancy after breast cancer are limited. Many young survivors are interested future fertility, but pregnancy rates among women attempting and not attempting pregnancy have not been studied prospectively. Methods: As part of a multicenter cohort study, women diagnosed age ≤40 with stage 0-3 breast cancer are surveyed at baseline then annually regarding fertility interest, attempts, and pregnancies. Chi-square tests were used to compare proportions attempting and achieving pregnancy. Results: At least once in the 5 years (yrs) after Dx, 334/959 (35%) women reported interest in future biologic children. The percent interested was stable in the first 3 yrs then declined: 256 (27%, baseline), 244 (27%, 1 year), 209 (25%, 2 yrs), 176 (25%, 3 yrs), 106 (18%, 4 yrs), and 72 (16%, 5 yrs). Pregnancy was attempted by 104/334 (31%) of women who reported interest and 4/625 (1%) who did not. Pregnancy occurred in 118 women (12%), including 76/108 (70%) who attempted and 42/851 (5%) who did not. Attempts and achieving pregnancy were associated with younger age, partnered status, and not having children prior to Dx (table). Lower stage was associated with attempting pregnancy and ER negative disease with achieving pregnancy. Conclusions: A substantial number of young women become pregnant in the 5 years after a breast cancer diagnosis. Given that over 1/3 of pregnancies were among women who did not report attempting, additional attention to contraception counseling should be considered. Further evaluation of assisted reproductive technology use, pregnancy and disease outcomes in this cohort, and the POSITIVE Trial (NCT02308085) will shed light on the feasibility and safety of pregnancy after breast cancer. [Table: see text]
Endocrine therapy non-persistence in young women with early-stage breast cancer.
Rosenberg, Shoshana M. , Gelber, Shari , Ruddy, Kathryn J. , Wasserman, Johanna, Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 531-531

10.1200/jco.2017.35.15_suppl.531 Get It

531 Background: The greatest age disparity in early stage breast cancer (BC) outcomes is in young women with hormone receptor positive (HR+) BC. While differences in biology may play a role, understanding the role of non-persistence (early discontinuation) with endocrine therapy (ET) is critical given the demonstrated efficacy of ET in this population. Methods: As part of a prospective cohort that enrolled women with BC diagnosed (dx) at age ≤40 between 2006-2016, we identified women with HR+, Stage I-III BC. Socio-demographic and treatment information, fertility concerns and confidence with the ET treatment decision were assessed by survey within 1 yr of dx. Medical record review was used to ascertain stage and HR status. Women who initiated ET but did not report taking tamoxifen or an aromatase inhibitor at 3 yrs post-diagnosis (or last follow-up if <3 yrs) were classified as non-persistent. Chi-square tests were used to compare categorical variables between persisters and non-persisters and stepwise multivariable regression to evaluate predictors of non-persistence. Results: In 538 women who initiated ET, median age at dx was 36; 10% were non-persistent. Discontinuation of ET was more likely in those who were less confident with their ET decision compared to those who were more confident (25/179, 14% vs 18/263, 7%, p=0.01). A greater proportion of women concerned about fertility discontinued vs. women not concerned (29/213,14% vs 25/319, 8%, p=0.03), and fertility concerns were associated with non-persistence in multi-variable analyses (OR: 1.85, 95% CI 1.05-3.26, p=0.03). Age at dx, race, education, employment, financial comfort, marital status, parity, stage, chemotherapy and local therapy were not associated with non-persistence. Conclusions: A significant minority of women with HR+ BC discontinued ET within 3 yrs. The association between fertility concerns expressed soon after dx and non-persistence underscores a need to address psychosocial issues that can impact treatment decisions in young women. Strategies to reduce decisional conflict and increasing confidence with the choice to take ET, may influence persistence. Future work will evaluate the contribution of other factors (eg symptom burden) to non-persistence.
Non-adherence behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann, Johanna , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 526-526

10.1200/jco.2017.35.15_suppl.526 Get It

526 Background: Young age at diagnosis (dx) is a predictor of worse prognosis in patients (pts) with luminal breast cancer (BC). Poorer adherence to endocrine therapy (ET) among younger women may contribute to this disparity. Aim: To assess non-adherent behaviors and associated factors among young women with stage 1-3 hormone receptor (HR)+ BC taking ET. Methods: This study is a part of a multi-center, prospective cohort of pts with dx of BC at or under age 40. On a survey 30 months after dx, among pts reporting taking ET, adherence was measured using a 3-item Likert-type scale (Do you ever forget to take your ET? If you feel worse when you take your ET, do you stop taking it? Did you take your ET exactly as directed by your doctor?). Pts reporting any non-adherent behavior during the last 3 months were classified as non-adherers. Variables with a p-value <0.20 were included in a multivariate logistic model. Results: Among361 pts eligible for this analysis, 174 (48%) reported some non-adherent behaviors in the last 3 months; 56 (16%) moderate or greater non-adherent behaviors. None of the studied variables was associated with non-adherent behaviors (table). Conclusions: Non-adherent behaviors to ET are present in almost half of the young women with HR+ BC. Further analyses of explanatory factors and impact of non-adherence are required to understand and potentially improve this problem. [Table: see text]
Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Collins, Laura C. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 533-533

10.1200/jco.2018.36.15_suppl.533 Get It

Quantitative T2 MRI Mapping and 12-Month Follow-up in a Randomized, Blinded, Placebo Controlled Trial of Bone Marrow Aspiration and Concentration for Osteoarthritis of the Knees
Arthurs, Jennifer R. , Kazmerchak, Shari E. , Diehl, Nancy N. , O’Connor, Mary I. , Bestic, Joseph M. , O'Connor, Mary I , Shapiro, Shane A. , Heckman, Michael G. , Zubair, Abba C.

Mayo Clinic

CARTILAGE | August 30, 2018 | Volume: 10 | Issue: 4 | Pages: 432-443

10.1177/1947603518796142 | PMID 30160168 Get It

Objective Bone marrow aspiration and concentration (BMAC) is becoming a more common regenerative therapy for musculoskeletal pathology. In our current pilot study, we studied patients with mild-to-moderate bilateral knee osteoarthritis, compared pain at 12-month follow-up between BMAC-injected and saline-injected knees, and examined cartilage appearance measured by magnetic resonance imaging (MRI) T2 quantitative mapping. Design Twenty-five patients with mild-to-moderate bilateral osteoarthritic knee pain were randomized to receive BMAC into one knee and saline placebo into the other. Bone marrow was aspirated from the iliac crests, concentrated in an automated centrifuge, combined with platelet-poor plasma for knee injection, and compared with saline injection into the contralateral knee. Primary outcome measures were T2 MRI cartilage mapping at 6-month and Visual Analog Scale and Osteoarthritis Research Society International Intermittent and Constant Osteoarthritis Pain scores and radiographs at 12-month follow-up. Results Constant, intermittent, and overall knee pain remained significantly decreased from baseline at 12-month follow-up (all P ⩽ 0.01), with no apparent difference between BMAC- and saline-treated knees (all P ⩾ 0.54). A similar significant increase from baseline to 12-month follow-up regarding quality of life was observed for both BMAC- and saline-treated knees (all P ⩽ 0.04). T2 quantitative MRI mapping showed no significant changes as a result of treatment. Conclusions BMAC is safe to perform and relieves pain from knee arthritis but showed no superiority to saline injection at 12-month follow-up. MRI cartilage sequences failed to show regenerative benefit with single BMAC injection. The mechanisms of action that led to pain relief remain unclear and warrant further studies.